Recent Advances in Understanding Pemphigus and Bullous Pemphigoid

被引：36
作者：
Hammers, Christoph M. [1 ,2 ]
Stanley, John R. [3 ]
机构：
[1] Univ Lubeck, Lubeck Inst Expt Dermatol, Lubeck, Germany
[2] Univ Lubeck, Dept Dermatol, Lubeck, Germany
[3] Univ Penn, Dept Dermatol, 421 Curie Blvd, Philadelphia, PA 19104 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2020年 / 140卷 / 04期
关键词：
INTRAVENOUS IMMUNOGLOBULIN; B-CELLS; TOPICAL CORTICOSTEROIDS; MONOCLONAL-ANTIBODY; COLLAGEN-XVII; DISEASE; AUTOANTIBODIES; VULGARIS; SKIN; COMPLEMENT;
D O I：
10.1016/j.jid.2019.11.005
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
For many years, The Journal of Investigative Dermatology (JID) has been a leader in our understanding of many aspects of the major autoimmune blistering skin diseases, pemphigus and bullous pemphigoid. The purpose of this review is to highlight and summarize those advances by discussing the respective articles, published in the JID from 2015 to 2019. Seminal articles from elsewhere in the literature that set the stage for those advances, or that are "classics" in the area, are also included to provide context and a more complete picture.
引用
收藏
页码：733 / 741
页数：9
相关论文
共 98 条
  • [11] Mucosal Pemphigus Vulgaris Anti-Dsg3 IgG Is Pathogenic to the Oral Mucosa of Humanized Dsg3 Mice
    Culton, Donna A.
    McCray, Suzanne K.
    Park, Moonhee
    Roberts, James C.
    Li, Ning
    Zedek, Daniel C.
    Anhalt, Grant J.
    Cowley, Dale O.
    Liu, Zhi
    Diaz, Luis A.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 (06) : 1590 - 1597
  • [12] Clonal Analysis of B-Cell Response in Pemphigus Course: Toward More Effective Therapies
    Di Zenzo, Giovanni
    Zambruno, Giovanna
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 (03) : 651 - 654
  • [13] ISOLATION OF A HUMAN EPIDERMAL CDNA CORRESPONDING TO THE 180-KD AUTOANTIGEN RECOGNIZED BY BULLOUS PEMPHIGOID AND HERPES-GESTATIONIS SERA - IMMUNOLOCALIZATION OF THIS PROTEIN TO THE HEMIDESMOSOME
    DIAZ, LA
    RATRIE, H
    SAUNDERS, WS
    FUTAMURA, S
    SQUIQUERA, HL
    ANHALT, GJ
    GIUDICE, GJ
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (04) : 1088 - 1094
  • [14] Du FH, 2017, AUTOIMMUN HIGHLIGHTS, V8, DOI 10.1007/s13317-017-0100-y
  • [15] Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
    Ellebrecht, Christoph T.
    Bhoj, Vijay G.
    Nace, Arben
    Choi, Eun Jung
    Mao, Xuming
    Cho, Michael Jeffrey
    Di Zenzo, Giovanni
    Lanzavecchia, Antonio
    Seykora, John T.
    Cotsarelis, George
    Milone, Michael C.
    Payne, Aimee S.
    [J]. SCIENCE, 2016, 353 (6295) : 179 - 184
  • [16] Pathogenic IgG4 autoantibodies from endemic pemphigus foliaceus recognize a desmoglein-1 conformational epitope
    Evangelista, Flor
    Roth, Aleeza J.
    Prisayanh, Phillip
    Temple, Brenda R.
    Li, Ning
    Qian, Ye
    Culton, Donna A.
    Liu, Zhi
    Harrison, Oliver J.
    Brasch, Julia
    Honig, Barry
    Shapiro, Lawrence
    Diaz, Luis A.
    [J]. JOURNAL OF AUTOIMMUNITY, 2018, 89 : 171 - 185
  • [17] IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants
    Freire, P. C.
    Munoz, C. H.
    Stingl, G.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (06) : 1644 - 1653
  • [18] Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous Pemphigoid
    Freire, Patricia Colchete
    Munoz, Cristina Herraez
    Derhaschnig, Ulla
    Schoergenhofer, Christian
    Firbas, Christa
    Parry, Graham C.
    Panicker, Sandip
    Gilbert, James C.
    Stingl, Georg
    Jilma, Bernd
    Heil, Peter Maximilian
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (12) : 2417 - +
  • [19] Gao JP, 2018, J INVEST DERMATOL, V138, P2307, DOI [10.1016/j.jid.2018.03.851, 10.1016/j.jid.2018.05.011]
  • [20] CLONING AND PRIMARY STRUCTURAL-ANALYSIS OF THE BULLOUS PEMPHIGOID AUTOANTIGEN BP180
    GIUDICE, GJ
    EMERY, DJ
    DIAZ, LA
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1992, 99 (03) : 243 - 250
12345678910